Company Overview and News


Add 533288
to your dashboard

Headline News

KiviHealth raises $400,000 in Pre-Series A round

2017-12-07 thehindubusinessline
KiviHealth, a technology platform that aims to create next-generation medical clinic using intelligence and automation, has raised $400,000 in pre-Series A round from Chandigarh Angels Network and Claris Capital, a wholly owned subsidiary of Ahmedabad-based pharma company Claris Lifesciences.

Claris Life promoter seeks delisting of shares

2017-12-02 thehindubusinessline
Claris Lifesciences today said it has received a letter from the promoter Athanas Enterprise Pvt Ltd to consider delisting of shares of the pharma company from the stock exchange.

Torrent Pharma in advanced talks to buy Unichem’s India business for Rs3,200-3,300 crore

2017-10-30 livemint
Mumbai: Torrent Pharmaceuticals Ltd is likely in advanced discussions to acquire the domestic formulations business of Unichem Laboratories Ltd for Rs3,200-3,300 crore, two people aware of the development said on the condition of anonymity. (36-0)

Claris Lifesciences rises 3% as RBI allows FPIs to raise stake to 49%

2017-10-18 moneycontrol
Claris Lifesciences share price gained 2.6 percent intraday Wednesday after the Reserve Bank of India has allowed foreign investors to raise their stake in the company to 49 percent.

RBI hikes Claris Lifesciences FPI investment limit to 49%; NRI limit at 24%

2017-10-18 indiainfoline
Foreign Institutional Investors (FIIs)/Foreign Portfolios Investors (FPIs) investment limit under Portfolio Investment Scheme in Claris Lifesciences Ltd has increased from 24%to 49% of its paid-up capital," the RBI said in a notification

Market Live: Sensex extends losses at open, Nifty holds 10,200; Axis Bank tanks 7%

2017-10-18 moneycontrol
10:00 am Listing: MAS Financial Services share price started off trade with a whopping premium of 44 percent on the National Stock Exchange. (25-0)

FII Investment under PIS.

2017-10-17 indiainfoline
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in “National Do Not Call Registry” as laid down by “Telecom Regulatory Authority of India” will not be applicable for such information/ communication. (4-0)

Claris Lifesciences net cash stands at Rs 381 per share, stock down 7.46%

2017-10-12 moneycontrol
Drug maker Claris Lifesciences said its net cash availability stands at Rs 2077 crore translating to Rs 381 per every single share, without considering taxes.

Claris studying options to distribute Rs 2,077 cr to its shareholders

2017-10-12 business-standard
Ahmedabad-headquartered Claris Lifesciences that recently completed the sale of its remaining 20 per cent stake in Otsuka Pharmaceutical India Private Limited (OPIPL), the joint venture with Otsuka Pharmaceutical Factory and Mitsui & Co, to Otsuka, on Thursday said that it is considering options (dividend or share buyback) to distribute around Rs 2,077 crore to its shareholders.   In a filing to the BSE, Claris Lifesciences said that the total cash available with the company is Rs 3,614 crore.

Late rally lifts Sensex 348 pts; Nifty tad below 10,100; RIL up 4% ahead of Q2 nos

2017-10-12 moneycontrol
It was a spectacular rally in late trade Thursday as the Sensex surged 375 points and the Nifty reclaimed 10,100 level intraday, backed by Reliance Industries, private banks, FMCG and metals stocks. The broader markets also participated in the rally, rising for the second consecutive session. (9-0)

Claris Lifesciences transaction raises investor concerns

2017-10-12 indiainfoline
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in “National Do Not Call Registry” as laid down by “Telecom Regulatory Authority of India” will not be applicable for such information/ communication.

Claris completes sale of its remaining 20% stake in Otsuka JV for Rs 130 cr

2017-09-22 business-standard
Ahmedabad-headquartered injectables player Claris Lifesciences has completed the sale of its remaining 20 per cent stake in Otsuka Pharmaceutical India Private Limited (OPIPL), the joint venture with Otsuka Pharmaceutical Factory and Mitsui & Co, to Otsuka for Rs 130 crore ($20 million).

Claris Lifesciences completes sale of its stake in JV to Otsuka

2017-09-21 indiainfoline
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in “National Do Not Call Registry” as laid down by “Telecom Regulatory Authority of India” will not be applicable for such information/ communication.

Carlyle Group merges growth, buyout verticals in India

2017-08-16 livemint
Mumbai: Carlyle Group, a global alternative asset manager with $170 billion of assets under management, is streamlining its operations in India by merging its growth and buyout investment departments as part of an effort to focus on more buyout transactions, according to two people aware of the development.

Top buzzing midcap stocks to trade on August 9

2017-08-09 moneycontrol
Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today -- Claris Lifesciences, SRF, Sun Pharmaceutical, JSPL, HDIL, Kaveri Seeds, Nalco, and NMDC.